MedTrace Logo

Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study

NCT01095874 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 164

Last updated 2014-01-20

No results posted yet for this study

Summary

The purpose of this study is to compare outcome of high risk myelodysplasia patients aged from 50 to 70 years with or without HLA compatible (9 or 10 identities / 10) donor. High risk myelodysplasia includes IPSS intermediate 2 and high myelodysplasia and patients with sever thrombocytopenia. Patients are registered when they acquire risk factors.

Conditions

  • Myelodysplasia

Sponsors & Collaborators

  • Hospital Avicenne

    collaborator OTHER

  • University Hospital, Grenoble

    collaborator OTHER

  • University Hospital, Clermont-Ferrand

    collaborator OTHER

  • Saint-Louis Hospital, Paris, France

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2014-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01095874 on ClinicalTrials.gov